CGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment

Darren D Browning, In Kiu Kwon, Rui Wang

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

In recent years, several antitumor signaling pathways mediated by the cGMP-dependent protein kinases have been identified in colon cancer cells. This review aims to present the mounting evidence in favor of cGMP/protein kinase G (PKG) signaling as a therapeutic strategy in colon cancer. The homeostatic and tumor suppressive effects of cGMP in the intestine are uncontested, but the signaling details are not understood. PKG is the central cGMP effector, and can block proliferation and tumor angiogenesis by inhibiting β-catenin/TCF and SOX9 signaling. Therapeutic activation of cGMP/PKG offers a promising avenue for the prevention and treatment of colon cancer, but additional preclinical studies are needed to fully understand the potential of this system.

Original languageEnglish (US)
Pages (from-to)65-80
Number of pages16
JournalFuture Medicinal Chemistry
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Cyclic GMP-Dependent Protein Kinases
Colonic Neoplasms
Protein Kinases
Catenins
Intestines
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

CGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. / Browning, Darren D; Kwon, In Kiu; Wang, Rui.

In: Future Medicinal Chemistry, Vol. 2, No. 1, 01.01.2010, p. 65-80.

Research output: Contribution to journalReview article

@article{634458671091410380e2f1fb29f5c22e,
title = "CGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment",
abstract = "In recent years, several antitumor signaling pathways mediated by the cGMP-dependent protein kinases have been identified in colon cancer cells. This review aims to present the mounting evidence in favor of cGMP/protein kinase G (PKG) signaling as a therapeutic strategy in colon cancer. The homeostatic and tumor suppressive effects of cGMP in the intestine are uncontested, but the signaling details are not understood. PKG is the central cGMP effector, and can block proliferation and tumor angiogenesis by inhibiting β-catenin/TCF and SOX9 signaling. Therapeutic activation of cGMP/PKG offers a promising avenue for the prevention and treatment of colon cancer, but additional preclinical studies are needed to fully understand the potential of this system.",
author = "Browning, {Darren D} and Kwon, {In Kiu} and Rui Wang",
year = "2010",
month = "1",
day = "1",
doi = "10.4155/fmc.09.142",
language = "English (US)",
volume = "2",
pages = "65--80",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "1",

}

TY - JOUR

T1 - CGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment

AU - Browning, Darren D

AU - Kwon, In Kiu

AU - Wang, Rui

PY - 2010/1/1

Y1 - 2010/1/1

N2 - In recent years, several antitumor signaling pathways mediated by the cGMP-dependent protein kinases have been identified in colon cancer cells. This review aims to present the mounting evidence in favor of cGMP/protein kinase G (PKG) signaling as a therapeutic strategy in colon cancer. The homeostatic and tumor suppressive effects of cGMP in the intestine are uncontested, but the signaling details are not understood. PKG is the central cGMP effector, and can block proliferation and tumor angiogenesis by inhibiting β-catenin/TCF and SOX9 signaling. Therapeutic activation of cGMP/PKG offers a promising avenue for the prevention and treatment of colon cancer, but additional preclinical studies are needed to fully understand the potential of this system.

AB - In recent years, several antitumor signaling pathways mediated by the cGMP-dependent protein kinases have been identified in colon cancer cells. This review aims to present the mounting evidence in favor of cGMP/protein kinase G (PKG) signaling as a therapeutic strategy in colon cancer. The homeostatic and tumor suppressive effects of cGMP in the intestine are uncontested, but the signaling details are not understood. PKG is the central cGMP effector, and can block proliferation and tumor angiogenesis by inhibiting β-catenin/TCF and SOX9 signaling. Therapeutic activation of cGMP/PKG offers a promising avenue for the prevention and treatment of colon cancer, but additional preclinical studies are needed to fully understand the potential of this system.

UR - http://www.scopus.com/inward/record.url?scp=77953462071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953462071&partnerID=8YFLogxK

U2 - 10.4155/fmc.09.142

DO - 10.4155/fmc.09.142

M3 - Review article

C2 - 21426046

AN - SCOPUS:77953462071

VL - 2

SP - 65

EP - 80

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 1

ER -